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The gap in mortality between patients with rheumatoid arthritis (RA) and the general population (1.5–3.0 fold risk) is increasing.
This disparity is attributable mainly to cardiovascular disease (CVD), as the CVD risk is comparable to patients with diabetes
mellitus. The purpose of this study is to determine whether borage seed oil rich in gamma-linolenic acid, ﬁsh oil rich in
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), or the combination of both oils are useful treatments for
dyslipidemia in patients with RA. We randomized patients into a double blind, 18 month trial. Mixed eﬀects models were used to
compare trends over time in serum lipids. No signiﬁcant diﬀerences were observed between the three groups: All three treatment
groups exhibited similar meaningful improvement in the lipid proﬁle at 9 and 18 months. When all groups were combined,
these treatments signiﬁcantly reduced total and LDL-cholesterol and triglycerides, increased HDL-cholesterol, and improved the
atherogenic index. All improvements observed at 9 months persisted at 18 months (P<0.001 verses baseline). Conclusion. Marine
and botanical oils may be useful treatment for rheumatoid arthritis patients who are at increased risk for cardiovascular disease
compared to the general population.
1.Introduction
Over the past 30 years, substantial progress has been made
in the medical and surgical management of patients with
rheumatoid arthritis (RA). Despite this progress, there is an
increasing gap in mortality between patients with RA (1.5–
3.0 fold risk) and the general population. The disparity is
mainly attributable to cardiovascular disease (CVD) [1]a s
theCVDriskiscomparabletopatientswithdiabetesmellitus
[2, 3]. Although the reasons for this gap are not entirely
clear, the traditional risk of abnormalities in lipid proﬁles [4]
appears to be enhanced by a chronic increase in inﬂamma-
tory cytokines [5], resulting in accelerated atherosclerosis. In
fact, the elevated risk of cardiovascular disease for patients
with RA indicates that atherosclerosis may in fact begin at
lower thresholds of lipid dysfunction and inﬂammation than
those in the general population, making the lipid proﬁle and
other risk factors of particular concern for patients with RA
[6]. In a prospective study, [7] atherogenic lipid proﬁles were
considerably worse in people who later met criteria for RA
(as much as 10 years later) than those in matched controls.
Although recent advances in the treatment of RA, especially
with agents designed to block the actions of tumor necrosis
factoralpha (TNFα), have improved the course of the disease
[8] and endothelial function [9], results of studies of their
inﬂuence on circulating lipids are mixed, and adequate
evidence for or against such beneﬁt is not available [10–12].
Due to the lack of supporting data, patients with RA, many
ofwhomarelimitedintheirabilitytoexercisetoimprovethe
lipid proﬁle and the risk of CVD [13], have an urgent need
for other treatments to control their dyslipidemia.
It is clear that an increased intake of polyunsaturated
fatty acids can improve their lipid proﬁle [14]. Abundant
experimental evidence supports the view that prostaglan-
dins, thromboxanes, and leukotrienes (collectively termed
eicosanoids), derived from polyunsaturated fatty acids, and2 Evidence-Based Complementary and Alternative Medicine
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participate in development and regulation of immunological
and inﬂammatory responses [15–18]. The fatty acids them-
selves, by virtue of their incorporation into cell membranes
and signal transduction elements, also have eﬀects on cells
involved in inﬂammation and immune responses that are
independent of eicosanoids [18, 19]. A disease such as RA,
characterized by abnormal immune responses, persistent
inﬂammation, and joint tissue injury [20], may, therefore, be
amenable to control by treatment with oils rich in speciﬁc
polyunsaturated fatty acids.
Gamma-linolenic acid (GLA: 18:3 omega 6, see Figure 1)
is an essential fatty acid found in certain plant seed oils, inc-
luding borage seed oil. GLA is metabolized to dihomoga-
mma-linolenic acid (DGLA; 20:3 omega 6), the immediate
precursor of prostaglandin E1 (PGE1), an eicosanoid with
anti-inﬂammatory and immunoregulatory properties [18].
In addition, GLA cannot be converted to inﬂammatory
leucotrienes by 5-lipoxygenase. Instead, it is converted to
15-hydroxy-DGLA which has the additional virtue of sup-
pressing 5-lipoxygenase activity [21]. GLA and DGLA also
modulate immune responses in an eicosanoid-independent
manner by acting directly on T lymphocytes [18]a n dG L A
suppresses acute and chronic inﬂammation, including arth-
ritis, in animal models [18]. In addition, ﬁsh oil, rich in
eicosapentaenoic acid (EPA; 20:5 omega 3, see Figure 2)a n d
docosahexanoic acid (DHA; 22:6 w-3), suppresses formation
of the inﬂammatory eicosanoids PGE2, thromboxane A2
(TXA2), and leucotriene B4 (LTB4). Randomized, placebo
controlleddoubleblindtrialsindicatedthatﬁshoiltreatment
of patients with RA result in clinical improvement, and those
that monitored NSAID use suggest that ﬁsh oil treatment has
an NSAID sparing eﬀect [22].
A combination of EPA- and GLA-enriched oils exhibits
synergy in reduction of synovitis in animal models [23], and
administration of black currant seed oil, which contains the
n-3 fatty acid alpha-linolenic acid (which is converted to
EPA)andthen-6GLA,suppressesactivesynovitis inpatients
with RA [24]. Taken together, these studies suggest that both
EPA and GLA are beneﬁcial therapies for patients with RA.
With this knowledge, we carried out an 18-month, multi-
center, randomized, double-blind, phase 3 trial of borage
seed oil, ﬁsh oil, and a combination of both oils in patients
with RA and active synovitis, to determine whether the
combination of oils is superior to either oil used alone for
the treatment of RA. Clinical outcomes of that study will be
presentedelsewhere.Theobjectofthestudypresentedhereis
to assess the inﬂuence of marine and botanical oils on serum
lipids in patients with RA.
2.Methods andMaterials
The study was an 18-month randomized double-blind
comparison of borage oil, ﬁsh oil, or a combination of both
oils in RA patients with active joint inﬂammation.Evidence-Based Complementary and Alternative Medicine 3
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Patients received 3.5gm omega-3 fatty acids daily in a
2 . 1g mE P A / 1 . 4g mD H Ar a t i o( 7ﬁ s ho i la n d6s u n ﬂ o w e ro i l
capsules daily), 1.8gm/dGLA (6 borage oil and 7 sunﬂower
oil capsules/d), or 7 ﬁsh oil and 6 borage oil capsules
daily (combination therapy). All capsules were identical in
appearanceandcolorandwerepurchasedfromthemanufac-
turer, Bioriginal Food and Service Corp, Saskatoon, Canada,
who shipped the capsules in opaque plastic bottles to the
University of Massachusetts University Hospital pharmacy,
from whence they were distributed to participating centers.
Capsules were taken in 2 or 3 divided doses with meals.
The protocol was reviewed and approved initially by
the Committee for the Protection of Human Subjects at
the University of Massachusetts Medical School and the
Food and Drug Administration. Subsequent approvals were
obtained from the Review Boards at the University of
Alabama, Geisenger Clinic, Fallon Health Care, and the New
England IRB. Written informed consent was obtained from
each patient.
Patients were eligible to participate in the study if
they had RA according to the 1987 criteria of the American
RheumatismAssociation[25],wereinfunctionalclassI,IIor
III according to the revised criteria of the American College
of Rheumatology [26], and were between the ages of 18 and
85. Patients were on a stable dose of drugs for RA for at
least 2 months before the screening visit and a total duration
of therapy of at least 6 months. Doses of nonsteroidal
anti-inﬂammatory drugs (NSAID) and/or prednisone
(<10mg/d) were stable for at least 1 month before screening.
Patients were ineligible for the study if they had been
treated with any investigational drug within 1 month of
entry. If a patient was taking a ﬁsh oil supplement, the dose
was stable and ≤2000mg/d for 2 months before screening. If
a patient was taking a borage oil supplement, the dose was
stable and ≤2000mg/d for 2 months before screening. An
AST, ALT, or creatinine >1.5 times the upper limit of normal
or a total bilirubin >1.8mg/dL excluded patients from the
trial. Patients were instructed to maintain their typical diet.
The lipid proﬁle was assessed at baseline, 9, and 18
months. Diet was assessed by 24-hour dietary assessment
calls (24-HR), performed at baseline and 18 months. Both
laboratory evaluation and 24-HR were obtained in most
patients who dropped out of the study before 18 months and
after3months.Theseresultsareincludedintheanalysis,and
were assigned to the closest 9-month interval to the date of
patient’s termination in the study.
2.1. Dietary Assessment. To measure the eﬀects of supple-
mental polyunsaturated fats upon lipids, it is necessary
to measure the impact, if any, of the background diet.
Because a single 24-HR cannot assess day-to-day variation in
dietary intake [27], 3 unannounced 24-HRs were conducted
on randomly selected days within a 3-week period (two
weekdays and one weekend) at baseline and 18 months or
time of the ﬁnal visit. The dietary assessments, including
reported intake of supplemental non-study marine and
botanical oils or phytosterols, were completed utilizing a
computer-assisted telephone interview with a multiple pass4 Evidence-Based Complementary and Alternative Medicine
technique [28]. The 24-HR dietary recalls were administered
by non-intervention registered dietitians, blinded to the
patients’ treatment group, and trained to collect dietary
data using our interview system. The 24-HR-derived data
were analyzed using the University of Minnesota Nutrition
Coordinating Center Nutrition Data System for Research
software (annually updated, current version: NDS-R 2009).
Limitations to 24-HR dietary assessment in this population
include factors related to self report, including possible
underreporting of nutrient intake which has been observed
in several studies [29].
2.2. Laboratory Measurement Methodology. Total cholesterol
(TC) and triglyceride (TG) values were measured by con-
ventional enzymatic methods. Brieﬂy, cholesterol esters are
converted to a colored quinine imine product. For HDL
cholesterol, the lipoprotein particles are solubilized and
release HDL cholesterol to react with cholesterol esterase and
oxidase in the presence of chromogens to produce a color
product. LDL cholesterol is calculated [30] according to the
Friedewald Calculation which is TC-HDL−(TG÷5) = LDL.
Atherogenic index of plasma (AIP) was used to measure the
risk of hypertension, diabetes, and vascular events in this
population. The calculation of AIP is log10 triglyceride/
high-density lipoprotein cholesterol [31].
2.3. Statistical Methods. The three treatment arms were
characterized at baseline using frequencies for categorical
variables and means and standard deviations for continuous
variables. Diﬀerences in mean values at 18 months or at the
ﬁnal visit were assessed for change in diet by the Student t-
test [23]. Outcomes that were not normally distributed were
log transformed for calculation of P values. Nontransformed
data are reported for changes from baseline. To assess the
eﬀectoftheintervention onlipids, lipid valuesweremodeled
usinglinearmixedmodelingasafunctionoftime(baseline,9
monthand18month,ortheﬁnalvisittreatedasacategorical
variable to allow for nonlinear trajectories), treatment arm,
and their interaction, with adjustment for baseline value.
To assess the overall changes over time, outcome measures
were modeled using linear mixed modeling as a function of
time, treatment arm, and with adjustment for baseline value.
All analyses were intention to treat. Analyses included all
participants with a baseline lipid measure.
3. Results
One hundred ﬁfty-six patients were randomized, 56 received
ﬁsh oil, 53 received borage seed oil, and 47 received both
ﬁsh and borage seed oils. Patients were stratiﬁed by site
(thus randomized to group within each site), and all sites
were combined, resulting in non-signiﬁcant diﬀerences per
group. Serum lipids were obtained in 146 patients (93.6%)
at baseline, 84 patients (53.8%) at 9 months, and 69 patients
(44.2%) at 18 months.
Another 34 patients were screened but not randomized
for the following reasons: arthritis medicine dose was not
stable, too few tender joints, anticoagulated, high ﬁsh oil
intake, high borage seed oil intake, medical issues, or
Table 1: Baseline characteristics in patients with rheumatoid
arthritis.
Total (N = 146)∗
Mean SD
Age 59.24 11.58
BMI (kg/m2) 30.55 8.3
N%
Gender
Male 28 19.2%
Female 118 80.8%
Marital status
Married 100 69.0%
Other 45 31.0%
Race-collapsed
White 132 90.4%
Minority 14 9.6%
Work status
Full time 51 34.90%
Part time 14 9.60%
Other 81 55.50%
∗None of the demographics are signiﬁcantly diﬀerent across the groups at
baseline.
abnormal laboratory values. The overall drop-out rate was
51% and was similar across groups: 25 in the borage oil
group, 28 in the ﬁsh oil group, and 22 in the combination
group. Reasons for dropout were mainly gastrointestinal
distress (belching, bloating, diarrhea, nausea, cramping) or
an inability to swallow the large number of rather sizable
capsules.
Patient characteristics at baseline are presented in
Table 1. The mean age of participants was 59 years and
the sample predominantly female (80%). Most were white
(90%), married (69%), and had a mean body mass index
(BMI)of30.5.Anequalnumberwereretired(33%)orwork-
ing full time (34%), and 16% listed themselves as disabled.
There were no signiﬁcant diﬀerences between groups.
3.1. Diet. No signiﬁcant change in dietary intake of fatty
acids was seen (Table 2). However, a signiﬁcant (P<0.001)
reduction in sources of dietary calcium (∼200mg) and a
slight increase (1% of total calories) in protein intake were
observed.
3.2. Weight. No signiﬁcant diﬀerences in weight between
groups were observed. Analysis was done using log-trans-
formed weight; however, results are from the original scale.
Themeanincreasewhenallgroupswerecombinedacrossthe
entire study was not signiﬁcant: 0.5lb increase at 9 months
and 0.4lb increase at 18 months (Table 4).
3.3. Lipids. There were no signiﬁcant diﬀerences between
groups for any lipid measure, with the exception of triglyc-
erides. Therefore, all groups were, combined to evaluate
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Table 2: Change in dietary factors from baseline to 18 months.
Change in Mean 95% CI
Energy 9.01 −121.17 to 139.19
Total dietary ﬁber −0.15 −1.75 to 1.45
Soluble dietary ﬁber −0.15 −0.64 to 0.33
Insoluble dietary ﬁber −0.05 −1.27 to 1.17
Calcium −204.48 −375.78 to −33.19∗
PUFA 18:3 (linolenic acid) −0.03 −0.22 to 0.16
% calories from fat −0.31 −2.28 to 1.65
% calories from SFA 0.09 −0.89 to 1.08
% calories from MUFA −0.13 −0.91 to 0.66
% calories from PUFA −0.26 −1.21 to 0.69
Omega-3-fatty Acids 0.13 −0.12 to 0.38
% calories from carbohydrate −1.34 −3.19 to 0.51
% calories from protein 1.17 0.13 to 2.21∗
∗Values are presented as regression coeﬃcient (95% CI) unless stated
otherwise and control from baseline values. P<0.001.
(Table 3(a)). Lipids were done at baseline, 9 months, 18
months, or when the patient terminated the trial.
Total cholesterol reduction from baseline was 3.4mg/dL
(P = 0.129) at 9 months and 8.4mg/dL (P ≤ 0.001)
at 18 months. LDL was reduced signiﬁcantly by 4.4mg/dL
at 9 months (P = 0.019) and 9.4mg/dL at 18 months
(P ≤ 0.001). HDL was signiﬁcant: 4.0mg/dL increase at 9
months (P ≤ 0.001) and 5.0mg/dL increase at 18 months
(P<0.001). TC/HDL ratio decreased signiﬁcantly over
the time of the trial: a 0.26 reduction at 9 months (P<
0.001) and a reduction of 0.43 at 18 months (P<0.001).
Triglycerides were log transformed for analysis and reporting
of P values. However, the coeﬃcients and the diﬀerences
reported are from the nonlog-transformed scale. Reductions
in triglyceride concentrations were observed in all 3 groups
(Table 3(a)).Theoveralldecreaseacrossthestudyperiodwas
22.0mg/dL at 9 months (P<0.001) and 24.4mg/dL at 18
months (P<0.001). The TG reduction in the group treated
with both oils was signiﬁcantly greater (P<0.031) than the
borage oil or ﬁsh oil groups at 9 months, a pattern that per-
sisted at 18 months (Table 3(b)). Atherogenic index of plasma
(AIP) was reduced in all 3 groups (Table 3(a)). The overall
decrease across the study period was 0.22 at 9 months (P<
0.001) and 0.26 at 18 months (P<0.001). The reduction in
theAIPwassigniﬁcantlygreater(P = 0.011)at9monthsand
18monthsinthegrouptreatedwithbothoilsthanthatinthe
groups treated with either oil alone (Table 3(b)).
3.4. Sensitivity Analysis of Lipids. A sensitivity analysis was
run to detect if missing data might have aﬀected the study
results. Missing data were imputed by substituting the
baseline value. Since this would be the worst case scenario,
in which all missing data return to baseline; analyses were
repeated with the imputed data. The intragroup diﬀerences
seen in triglyceride concentrations were not sustained with
the imputed data. However, the intragroup diﬀerences seen
with the AIP did persist. The signiﬁcant change seen with
all groups combined was also sustained with the imputed
data,whichindicatesthatmissingdatawouldnothavealarge
impact on results from the all groups combined analyses.
3.5. Blood Pressure. Signiﬁcant changes in blood pressure
within and among groups were not observed. Systolic blood
pressure increased 1.8mmhg at 9 months and decreased
0.2mmhg at 18 months. Diastolic blood pressure increased
2.3mmhg at 9 months and 1.9mmhg at 18 months
(Table 4).
3.6. Erythrocyte Sedimentation Rate (ESR) [32] and C-React-
ive Protein (CRP). ESR is a common hematology test that
is a nonspeciﬁc measure of inﬂammation. CRP is a protein
found in the blood, and its levels increase in response to
inﬂammation.
No signiﬁcant diﬀerences in ESR or in CRP were seen
among groups. However, when patients from all treatment
groups were analyzed together, a modest but signiﬁcant
reduction in ESR was seen at 9 months, and ESR was still
reduced from baseline at 18 months. A similar small but
signiﬁcant reduction in CRP was seen at 9 months, but not
maintained at 18 months (Table 4).
4. Discussion
Part of the intrigue of research is the often unanticipated
ﬁndings encountered. The current study was not designed
to detect diﬀerences in lipids in patients with RA; hence,
we lack a control group. Because marine and botanical oils
given individually reduce joint inﬂammation in RA patients
[14–18], and because the groups in this study showed
improvement in the lipid proﬁle, a trial of these oils with a
placebo arm is warranted.
RAisachronicsystemicinﬂammatorydisease.Mediators
of inﬂammation and prothrombotic factors contribute to
endothelial dysfunction and development of cardiovascular
disease in RA patients [33]. There is little evidence that
therapy for inﬂammation also leads to cardiovascular risk
reduction in this group. Marine and botanical oils represent
an excellent primary or secondary therapy for improvement
of cardiovascular risk management in patients with rheuma-
toid arthritis.
Results of studies presented in this paper indicate that a
GLA-enriched botanical oil (borage seed oil), an EPA/DHA-
enriched ﬁsh oil, or a combination of these oils are useful for
correcting dyslipidemia in patients with RA. Since there were
nodiﬀerencesobservedbetweenthegroups,withthenotable
exception of triglycerides and the AIP (shown separately
in Table 3(b)), all 3 treatment groups were analyzed as a
single group. Although lipid proﬁles of most patients were
acceptable at baseline, patients taking these oils exhibit sig-
niﬁcant additional reductions in total and LDL cholesterol,
triglycerides, the TC/HDL ratio, and the atherogenic index,
and experience a signiﬁcant increase in HDL cholesterol. All
of these improvements in the lipid proﬁle were seen after
9 months of therapy and increased after 18 months of oils
administration. Particularly noteworthy is the group treated
with both oils, as they experienced a signiﬁcantly greater
reduction in serum triglyceride concentrations and in the
AIP than the groups on either oil alone. Oils enriched in6 Evidence-Based Complementary and Alternative Medicine
Table 3
(a) Serum Lipids and Atherogenic Index of Plasma
Baseline mean (SD) (N = 145) Change from baseline to 9 months
(N = 83)
Change from baseline to 18
months (N = 69)
Total cholesterol 195.77 (37.48)
−3.45
(−7.88 to 0.98)
−8.43∗
(−12.99 to −3.86)
LDL 114.63 (32.20)
−4.39∗∗
(−8.03 to −0.74)
−9.43∗
(−13.75 to −5.11)
HDL 54.14 (16.21) 3.96∗
(2.44 to 5.49)
5.02∗
(3.24 to 6.81)
TC/HDL ratio† 3.83 (1.03)
−0.26∗
(−0.41 to −0.12)
−0.43∗
(−0.58 to −0.28)
Triglyceride† 138.05 (79.65)
−21.96∗
(−30.52 to −13.40)
−24.42∗
(−33.22 to −15.61)
Atherogenic index of plasma 0.84 (0.67)
−0.22∗
(−0.29 to −0.16)
−0.26∗
(−0.33 to −0.19)
Values are presented as regression coeﬃcient (95% CI) unless stated otherwise and control from baseline values. ∗P<0.001 ∗∗P ≤ 0.05 †P value are
from log-transformed data.
(b) Triglycerides and atherogenic index of plasma (AIP) by group
Combination group Fish oil group Borage oil group P value
Triglyceride∗∗ 0.031
9m o n t h s −30.81
(−46.58 to −15.03)
−20.50
(−35.16 to −5.85)
−16.57
(−30.86 to −2.27)
18 months −38.24
(−54.28 to −22.19)
−15.27
(−29.81 to −0.74)
−22.10
(−37.32 to −6.89)
AIP 0.011
9m o n t h s −0.33
(−0.45 to −0.20)
−0.20
(−0.32 to −0.08)
−0.17
(−0.33 to 0.002)
18 months −0.45
(−0.57 to −0.32)
−0.16
(−0.28 to −0.05)
−0.21
(−0.33 to −0.09)
∗∗P valueisfromlogtransformation. Changesshown are fromtheoriginalscale for thegroup ×timeinteractionandcontrolfor baselinevalues.Values
are presented as regression coeﬃcient (95% CI).
Table 4: Change from baseline for anthropometric and inﬂamma-
tory markers.
9m o n t h s( N = 88) 18 months (N = 71)
Weight† 0.52
(−1.41 to 2.46)
0.35
(−2.43 to 3.14)
Systolic blood
pressure
1.77
(−0.66 to 4.20)
−0.24
(−3.37 to 2.90)
Diastolic blood
pressure
2.32∗
(0.56 to 4.09)
1.88∗∗
(−0.003 to 3.79)
ESR† −5.39∗
(−9.71 to −1.07)
−4.42∗∗
(−9.22 to 0.38)
CRP† −0.65∗
(−1.20 to −0.10)
−0.09
(−0.77 to 0.60)
∗P<0.001.
∗∗P ≤ 0.05.
†P values are from log-transformed data.
N = 90 at 9 months and N = 72 at 18 months for blood pressure measu-
rements.
N = 81 at 9 months and N = 67 at 18 months for ESR.
N = 66 at 9 months and N = 58 at 18 months for CRP.
GLA aﬀect inﬂammation diﬀerently than oils enriched in
EPA/DHA, and the anti-inﬂammatory and joint protective
eﬀects of the combination of these oils are synergistic
in animal models [23]. Thus, it is possible that these
diﬀerent oils inﬂuence diﬀerent aspects of TG synthesis or
metabolism. Indeed, ﬁsh and botanical oils that provide EPA
both reduce hepatic synthesis of TG in rats [34]. In humans
the delta-5-desaturase that converts DGLA to arachidonic
acid (AA) is sluggish, and we have not seen increases in
circulating arachidonic acid after administration of GLA
for 24 weeks [17]. Nonetheless, the possibility of increased
circulating AA must be considered if treatment is to be long
term.Whenﬁshoilisadministeredwithborageoiltohealthy
individuals, bioconversion of GLA to AA is prevented [34],
perhaps another reason for administering both GLA- and
EPA-rich oils together.
A l lt r e a t m e n t sw e r es a f e .R a t e sa n dt y p e so fa d v e r s e
events were similar across all treatment groups, and as
anticipated, were due entirely to mild to moderate gastroin-
testinal distress. The main reason for the large drop-out
rate (in excess of 45%) was the large size and the numberEvidence-Based Complementary and Alternative Medicine 7
of capsules ingested each day over the 18-month-study
period. It is possible to deliver much larger amounts of the
individualpolyunsaturatedfattyacids(GLA,EPA,andDHA)
in far smaller capsules than are needed to accommodate the
natural marine and botanical oils, a strategy which should
substantially reduce the dropout rate.
Alterations in diet can inﬂuence serum lipid concentra-
tions [35]. However, the patients in our study did not change
their diets over the course of the trial, suggesting that the
improvementsintheirlipidproﬁles,includingthesigniﬁcant
increase in HDL cholesterol, are due to administration
of the study oils. Most pharmacological treatments of
dyslipidemia address reduction of LDL cholesterol [36, 37].
Since improvement in HDL cholesterol depends to a large
extent on an exercise regimen [13, 38], many patients with
RA are denied this manner of therapy. Thus, treatment with
one or a combination of these oils could aid in the reduction
of cardiovascularrisk in RA patients whosedisability impairs
or prevents a prescribed exercise program.
Although LDL-C is the primary target of lipid-lowering
therapy, other measures of the lipoprotein lipid proﬁle, as
reﬂected in the AIP and the TC/HDL-C ratios, are also
associated with CVD risk. The AIP is a useful monitor of the
lipid proﬁle and its subsequent impact on the progression
of cardiovascular risk [39]. In the study presented here, the
AIP is signiﬁcantly and beneﬁcially altered at both 9 and
18 months compared to baseline. Patients in this study also
exhibit a signiﬁcant reduction in the TC/HDL ratio at 9
and 18 months, another indication of reduced CVD risk
[40]. The safety of marine and botanical oils, and their
remarkable impact observed in this study on the lipid proﬁle
of RA patients who are at increased risk for dyslipidemia and
cardiovascular disease [1], suggest that these oils should have
a prominent role in therapy of patients with RA.
Additionally, there is some evidence [41] that these oils
can substitute for treatment of RA patients with nonsteroidal
anti-inﬂammatory drugs (NSAIDs). The adverse gastroin-
testinal and renal events associated with NSAID therapy are
well known [42]. In addition, macrophages treated with a
cyclooxygenaseinhibitorinvitroexhibitgreatervulnerability
to formation of foam cells, a key element in development of
atheromatous plaques [43]. Neither borage oil nor ﬁsh oil
is associated with serious gastrointestinal events (ulceration,
bleeding,perforation).Inaddition,whereasNSAIDsincrease
the incidence of myocardial infarction and stroke [44], ﬁsh
oilreducestheriskofcardiovasculareventsinpatientsatrisk,
including those with RA [45]. The eﬃcacy of omega-3-fatty
acids in reducing mortality after a myocardial infarction [46]
is further reason to recommend their use in patients with
RA. Although studies in humans of the inﬂuence of GLA
on serum lipids are scant, GLA administration appears to
prevent increases in TC and LDL-C [47].
5. Conclusion
Chronic inﬂammation, experienced by patients with RA,
includes development of microthrombi in small vessels and
production of inﬂammatory cytokines and is associated with
accelerated atherosclerosis [48]. The capacity of both GLA-
and EPA-rich oils to reduce platelet aggregation [49]a n d
production of inﬂammatory cytokines [18] and the ability
of EPA to form resolvins and protectins, compounds that
facilitate resolution of inﬂammation [50], further suggest
their potential long-term therapeutic value in patients with
RA. The current study suggests their beneﬁcial eﬀect on
cardiovascular risk factors in patients with RA. Additional
studies of marine and botanical polyunsaturated fatty
acids—in isolated form in order to reduce the number
and the size of capsules administered—are warranted to
further determine their inﬂuence on lipid dysfunction in
patients with RA and other diseases characterized by chronic
inﬂammation.
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